Savant Capital LLC Purchases Shares of 16,543 Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Savant Capital LLC acquired a new position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 16,543 shares of the company's stock, valued at approximately $2,258,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of NBIX. Golden State Wealth Management LLC purchased a new stake in Neurocrine Biosciences during the 4th quarter worth approximately $25,000. Brooklyn Investment Group grew its position in Neurocrine Biosciences by 99.1% during the 4th quarter. Brooklyn Investment Group now owns 231 shares of the company's stock worth $32,000 after purchasing an additional 115 shares during the last quarter. Blue Trust Inc. grew its position in Neurocrine Biosciences by 171.9% during the 3rd quarter. Blue Trust Inc. now owns 348 shares of the company's stock worth $40,000 after purchasing an additional 220 shares during the last quarter. R Squared Ltd purchased a new stake in Neurocrine Biosciences during the 4th quarter worth approximately $61,000. Finally, UMB Bank n.a. grew its position in Neurocrine Biosciences by 211.6% during the 4th quarter. UMB Bank n.a. now owns 455 shares of the company's stock worth $62,000 after purchasing an additional 309 shares during the last quarter. Hedge funds and other institutional investors own 92.59% of the company's stock.

Insider Transactions at Neurocrine Biosciences

In related news, CFO Matt Abernethy sold 1,283 shares of the firm's stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $152.87, for a total transaction of $196,132.21. Following the completion of the sale, the chief financial officer now directly owns 32,681 shares in the company, valued at approximately $4,995,944.47. This trade represents a 3.78 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Kevin Charles Gorman sold 5,844 shares of the firm's stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $116.69, for a total transaction of $681,936.36. Following the sale, the director now owns 521,618 shares of the company's stock, valued at approximately $60,867,604.42. The trade was a 1.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 236,600 shares of company stock valued at $34,348,261 over the last 90 days. 4.30% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the stock. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Neurocrine Biosciences in a research report on Tuesday, February 11th. They set a "hold" rating and a $138.00 target price on the stock. StockNews.com raised shares of Neurocrine Biosciences from a "buy" rating to a "strong-buy" rating in a research report on Monday, February 10th. Needham & Company LLC reaffirmed a "hold" rating on shares of Neurocrine Biosciences in a report on Friday, February 7th. Guggenheim dropped their price objective on shares of Neurocrine Biosciences from $165.00 to $163.00 and set a "buy" rating on the stock in a report on Monday, February 10th. Finally, Barclays upped their price objective on shares of Neurocrine Biosciences from $160.00 to $165.00 and gave the company an "overweight" rating in a report on Monday, December 23rd. Five investment analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $166.90.

Neurocrine Biosciences Trading Down 1.6 %

NASDAQ:NBIX traded down $1.85 during trading hours on Friday, reaching $115.02. 1,479,784 shares of the company were exchanged, compared to its average volume of 952,604. Neurocrine Biosciences, Inc. has a twelve month low of $110.95 and a twelve month high of $157.98. The firm has a market cap of $11.65 billion, a PE ratio of 34.96 and a beta of 0.33. The stock's 50-day moving average is $137.83 and its 200-day moving average is $130.46.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last released its earnings results on Thursday, February 6th. The company reported $1.00 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.62 by ($0.62). Neurocrine Biosciences had a return on equity of 13.45% and a net margin of 14.49%. As a group, research analysts anticipate that Neurocrine Biosciences, Inc. will post 6.53 EPS for the current year.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.